| Document |
Document Title |
|
JP2005519115A |
The present invention provides a process for the preparation of a prostamide which comprises the steps of (d) reacting first intermediate having the general formula (I) with DIBAL wherein Z is a protecting group and the dotted line repre...
|
|
JP3664488B2 |
A process for producing an intermediate for a 13,14-didehydroprostaglandin E, represented by general formula (I), (wherein R<6> represents -COOR<9>, cyano, hydroxy, -OCOR<1><0> or -CONR<1><1>R<1><2>; A represents vinylene, ethynylene, ph...
|
|
JP3650258B2 |
To obtain the subject composition capable of manifesting excellent lowering of the intraocular tension without causing remarkable adverse side effects by making the composition include a specific compound therein. This composition contai...
|
|
JP3625946B2 |
|
|
JP3612067B2 |
A thermoelectric sensor element that is adapted to respond to thermal radiation is capable of manufacture into a sensor array on a single crystal semiconductor means, such as silicon. An anisotropically etched pit is provided under the s...
|
|
JP3612178B2 |
The present invention relates to the use of certain prostaglandin derivatives for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension. It also relates to a respective opthalmological composition.
|
|
JP2004537529A |
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the gener...
|
|
JP3600630B2 |
|
|
JP2004346080A |
To obtain an ocular hypotensive and a smooth muscle relaxant.This invention relates to a cyclopentane heptanoic acid substituted in the 1-position with a halo, methyl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, ether or t...
|
|
JP2004535465A |
The present invention is a novel intermediate, compound of the formula (VI)and salts thereof. In addition, the invention includes a process for the preparation of a 15(S)-prostaglandin intermediates compounds (IV) and (XVIII) which compr...
|
|
JP3588133B2 |
|
|
JP3579448B2 |
PURPOSE: To obtain a new prostaglandin derivative which is useful as an intraocular hypotensor without side effect such as transient intraocular hypertention. CONSTITUTION: The compound of formula I (R1 is H, a 1-10C alkyl; R2 is a 3-10C...
|
|
JP3573482B2 |
|
|
JP3573480B2 |
|
|
JP2004529973A |
The present invention provides a new and effective process for the synthesis of 17-phenyl-18,19,20-trinor-PGF2alpha and its derivatives, including the anti-glaucoma drugs Bimatoprost and Latanoprost. The benefit of the present invention ...
|
|
JP2004529166A |
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma a therapeutically effective amount of a 3, 7 or 3 and 7 thia or oxa pro...
|
|
JP3565857B2 |
PCT No. PCT/EP94/00215 Sec. 371 Date Dec. 4, 1996 Sec. 102(e) Date Dec. 4, 1996 PCT Filed Jan. 27, 1994 PCT Pub. No. WO95/20563 PCT Pub. Date Aug. 3, 1995The invention relates to leukotriene-B4 derivatives of general formula I, (I) in wh...
|
|
JP3541421B2 |
PURPOSE: To obtain a new compound useful as a medicine among various kinds. CONSTITUTION: The objective compound of formula I[W is (α-OZc, β-H) (Zc is a H- or OH-protecting group) or (α-H, β-OZc); (h) is 0-2; (m) is 0-5; Z2 is OH, CO...
|
|
JP3534433B2 |
PURPOSE: To provide a new antithrombotic agent having excellent drug action compared with conventional PGE1-type antithrombotic agent, keeping the action over a long period and exhibiting reduced side effect. CONSTITUTION: The antithromb...
|
|
JP2004511446A |
The present invention provides a novel compound represented by the general formula I;wherein R is H or COR3;R1 is H, R2, phenyl, or COR3, wherein R2 is C1-C5 lower alkyl and R3 is R2 or phenyl;Z is CH2 or O;Y is OH or OCOR3;x is 0 or 1; ...
|
|
JP3506485B2 |
PURPOSE: To obtain a prostaglandin (PG) derivative having excellent characteristics as an intraocular pressure-lowering agent, and eliminated or remarkably reduced in side effects such as transient intraocular pressure elevation. CONSTIT...
|
|
JP3503904B2 |
PURPOSE: To industrially and advantageously obtain E type prostaglandins useful as a medicine, etc., by reacting a lower alkyl ester of specific E type prostaglandins with an esterase which is produced by microorganisms belonging to the ...
|
|
JP3502952B2 |
PURPOSE: To obtain a new (9R-chloro)prostaglandin derivative having strong improving actions on nephropathy, ischemic cardiopathy and cardiac failure. CONSTITUTION: The compound of formula I (R is 4-8C cycloalkyl, 5-9C cycloalkylmethyl o...
|
|
JPWO2001094309A1 |
As a compound having both receptor antagonism of thromboxane A2 and prostaglandin D2, the formula (I): (in the formula, A may have an unsaturated bond alkylene; R is -C (= O). -R1 etc .; R1 is hydroxy etc .; m is 0 or 1; p is 0 or 1; X1 ...
|
|
JP3488456B2 |
The present invention concerns 2-decarboxyl-2-aminoalkyl derivatives of naturally occurring and synthetic prostaglandins, N-substituted derivatives, ester prodrugs and homologues of such compounds that are potent ocular hypotensives, and...
|
|
JP3480549B2 |
To obtain the subject new compound having excellent intraocular pressure-decreasing activities, hardly providing eye irritation and influence to ocular tissue such as cornea, iris and conjunctiva, and also excellent in persistance of the...
|
|
JP3479985B2 |
PURPOSE: To provide a platelet aggregation-inhibiting agent containing a prostaglandin E1 analogue as an active ingredient, excellent in its medicinal effect, good in durability, and not inducing the diarrhea of adverse action. CONSTITUT...
|
|
JP2003321442A |
To provide a prostaglandin (PG) derivative having an amidated carboxyl group at the 1st site and two fluorine atoms at the 15th site and useful as pharmaceuticals, and pharmaceuticals containing the derivative as an active component, esp...
|
|
JP2003531824A |
Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into op...
|
|
JP2003528897A |
A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
|
|
JP3446225B2 |
PURPOSE: To provide a new compound derivative produced by reacting a specific cyclopentenone derivative with a nucleophilic reagent and deprotecting the protecting group and useful as pharmaceuticals, agricultural chemicals or their inte...
|
|
JP2003523935A |
Prostaglandin and analogs thereof which include protective groups attached to at least one site which are pharmaceutically acceptable and which are capable of slowing the metabolic rate of the active groups for administration to a warm b...
|
|
JP2003523976A |
Compounds of Formula 1, where the symbols are as defined in the specification, are useful as ocular hypotensive agents but do not exert their activity through the FP prostaglandin receptor.In particular the compound PGF2alpha 1-ethanolam...
|
|
JP2003520848A |
Disclosed is a process for the preparation of the anti-glaucoma drug Latanoprost, in good yield, in large amounts and with desired purity. Also disclosed are novel intermediates for the above process.
|
|
JP3408835B2 |
PURPOSE: To suppress production of by-products and obtain the subject compound in a short period and high yield by reacting an enzyme derived from a microorganism belonging to the genus Aspergillus, Pseudomonas, etc., with a lower alkyl ...
|
|
JP3363489B2 |
PURPOSE: To provide the novel prostagrandin derivative having an excellent platelet aggregation-inhibiting action. CONSTITUTION: (17S)-3,7-interphenylene-3-oxa-4,5,6-tri-nor-17,20-dimethyl-
13,14- didehydro-PGE1. This compound is obtaine...
|
|
JP2002538138A |
Compounds having a structure according to the following formula:are effective in treating disorders such as bone disorders and glaucoma in a subject in need thereof.
|
|
JP2002293771A |
To provide a prostaglandin derivative useful as a treating agent or the like for glaucoma or ocular hypertension.The 15-deoxy-15,15-difluoroprostaglandin derivative or its salt is expressed by the formula (1), wherein, A is an ethylene g...
|
|
JP2002265437A |
To obtain a new clavulone expected to develop physiological activity and to provide a method for simultaneously and simply synthesizing various kinds of clavulones including the new clavulone.A method for combinatorial synthesis is used....
|
|
JP3316018B2 |
|
|
JP3316050B2 |
|
|
JP3313174B2 |
PURPOSE: To selectively and readily produce E type prostaglandins having cis double band in the α-chain or their esters in good yield. CONSTITUTION: E type prostaglandins or their esters of formula I (R is H, 1-4C alkyl or substitutable...
|
|
JP3304477B2 |
PURPOSE: To obtain the subject compound as an intermediate for prostaglandins in a high yield and through short steps under neutral and mild conditions without troubles such as preparing unstable anionic reagent (s). CONSTITUTION: The co...
|
|
JP2002518475A |
The invention relates to the use of an oxidation inhibitor, i.e. active carbon, for ambient air in industrial manufacturing, especially in the processing of prostane derivatives, whereby the oxidation inhibitor removes ozone from the pro...
|
|
JP2002161082A |
To provide a new prostaglandin derivative having vascular smooth muscle proliferation inhibitory effect, thus highly promising as a prophylactic or therapeutic agent for diseases including reconstriction after PTCA.This new compound is a...
|
|
JP2002155046A |
To provide a new PG derivative which is strongly expected to be a medicine for preventing and treating a disease such as restenosis after PTCA and has a vascular smooth muscle proliferation-inhibiting action.This prostaglandin derivative...
|
|
JP2002509916A |
The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R1, R2, R3, R4, R5, R6, W, X, Z, a, b, p and q are defined below. This inve...
|
|
JP2002509915A |
The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R1, R2, R3, R4, R5, R6, W, X, Z, a, b, p and q are defined below. This inve...
|
|
JP2002505321A |
The invention relates to novel process for the preparation of prostaglandin compounds which are useful as medicaments.
|
|
JP2002500646A |
PCT No. PCT/EP98/03139 Sec. 371 Date Mar. 27, 2000 Sec. 102(e) Date Mar. 27, 2000 PCT Filed May 22, 1998 PCT Pub. No. WO98/52915 PCT Pub. Date Nov. 26, 1998Leukotriene-B4 derivatives of general formula (I), in which R1 represents H, CF3,...
|
